Tetracyte

TetraCyte is a preclinical-stage biotechnology company dedicated to developing innovative cell therapies for neurodegenerative and rare genetic disorders. The company leverages a proprietary platform to engineer and transplant functional microglia—the resident immune cells of the central nervous system—derived from induced pluripotent stem cells (iPSCs). This approach aims to restore the brain's homeostatic environment and clear pathological protein aggregates, such as amyloid-beta and tau, which are central to diseases like Alzheimer's and Parkinson's. TetraCyte's technology is based on pioneering research from Stanford University and utilizes a unique brain-restricted preconditioning method to ensure high engraftment. Headquartered in Menlo Park, California, the company is backed by prominent venture capital firms including Andreessen Horowitz and 8VC.